Denali Therapeutics Inc. DNLI Business Segments — External research and development expense

Similar metrics at other companies

BEAMExternal Research And Development Expenses — Research And Development Expense

$30.08M-12.6%

IBRXReportable Segment — External research and development expense (including amounts with related parties)

$20.08M+264%

TVTXReportable Segment — External research and development

$27.73M+24.0%

INSMOther external R&D expenses — R&D

$32.68M+16.4%

IRONOther Research — Research And Development Expense

$2.17M+18.2%

IDYAIDE397 — External Clinical Development Expenses

$3.52M-6.0%

Other financials

Income statement

See full

Revenue-—

Operating income-$137.4M+5.6%

Net income-$128.4M+3.4%

EPS (diluted)-$0.69+11.5%

Balance sheet

See full

Cash & equivalents$390.7M+551%

Total debt$40.0M-22.3%

Total equity$926.1M-17.5%

Total assets$1.3B-0.4%

Cash flow

See full

Operating cash flow-$131.2M+0.2%

CapEx$2.5M-51.4%

Free cash flow-$133.7M+2.1%

Valuation

See full

Market cap$3.93B+54.2%

Profitability

See full

Operating margin-37,938%-37,986pp

Net margin-33,121.9%-33,159pp

FCF margin-31,736.3%-31,830pp

Returns & leverage

See full

Return on equity-49.6%+34.2pp

Debt / equity0×0.0×

Current ratio9.3×-0.3×

Where this comes from

Reported directly by Denali Therapeutics Inc. in its filing.

Tagged under the XBRL concept dnli:ExternalResearchAndDevelopmentExpense.

The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Denali Therapeutics Inc.'s business segments — external research and development expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Denali Therapeutics Inc.'s business segments — external research and development expense?: Denali Therapeutics Inc. (DNLI) reported business segments — external research and development expense of $38.46M in Q1 2026.
What does business segments — external research and development expense mean?: Represents costs incurred for third-party research and development activities, including payments to external partners or contract research organizations. This metric tracks the company's reliance on external collaboration to advance its therapeutic pipeline. Monitoring these expenses helps investors assess the efficiency of outsourced innovation versus internal development efforts.